Literature DB >> 31029010

Tumor-induced osteomalacia - Current imaging modalities and a systematic approach for tumor localization.

Sampanna Jung Rayamajhi1, Randy Yeh2, Tony Wong3, Shifali Dumeer3, Bhagwant Rai Mittal4, Fabrizio Remotti5, Ijeuru Chikeka5, Arun K Reddy4.   

Abstract

Paraneoplastic syndromes are symptom complexes that cannot be readily explained by local or distant spread of the tumor. They can occur due to hormone production, autoimmunity or other biologically active products produced by the tumor, etc. Tumor induced osteomalacia is a rare paraneoplastic syndrome in which the manifestation is mainly musculoskeletal such as bone pain, fractures and muscle weakness as a consequence of elaboration of fibroblast growth factor 23 (FGF23) by the tumor. Most of these tumors are solitary and small and hence localization of these tumors is often challenging. This review summarizes the various anatomic imaging modalities such as plain radiographs, computed tomography (CT), and magnetic resonance imaging (MRI) and nuclear medicine imaging techniques in the evaluation of these tumors.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DOTATATE; FGF23; Octreoscan; Phosphaturic mesenchymal tumor; Tumor-induced osteomalacia (TIO)

Mesh:

Year:  2019        PMID: 31029010     DOI: 10.1016/j.clinimag.2019.04.007

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  13 in total

Review 1.  Paraneoplastic musculoskeletal disorders: review and update for radiologists.

Authors:  Kimia Khalatbari Kani; Jack A Porrino; Michael E Mulligan; Felix S Chew
Journal:  Skeletal Radiol       Date:  2022-05-23       Impact factor: 2.199

Review 2.  Disorders of phosphate homeostasis in children, part 2: hypophosphatemic and hyperphosphatemic disorders.

Authors:  Richard M Shore
Journal:  Pediatr Radiol       Date:  2022-05-10

Review 3.  New Therapies for Hypophosphatemia-Related to FGF23 Excess.

Authors:  Diana Athonvarangkul; Karl L Insogna
Journal:  Calcif Tissue Int       Date:  2020-06-05       Impact factor: 4.333

4.  Epidemiology of Tumor-Induced Osteomalacia in Denmark.

Authors:  Bo Abrahamsen; Christopher D Smith; Salvatore Minisola
Journal:  Calcif Tissue Int       Date:  2021-04-05       Impact factor: 4.333

5.  Lessons learnt from delayed diagnosis of FGF-23-producing tumour-induced osteomalacia and post-operative hungry bone syndrome.

Authors:  S Kumar; T Diamond
Journal:  Bone Rep       Date:  2020-05-06

6.  Usefulness of 68Ga-DOTATOC PET/CT to localize the culprit tumor inducing osteomalacia.

Authors:  Dong Yun Lee; Seung Hun Lee; Beom-Jun Kim; Wanlim Kim; Pil Whan Yoon; Sang Ju Lee; Seung Jun Oh; Jung-Min Koh; Jin-Sook Ryu
Journal:  Sci Rep       Date:  2021-01-19       Impact factor: 4.379

7.  Tumor-Induced Osteomalacia Localized and Excised After Pregnancy.

Authors:  Melissa Sum; Syed T Hoda; Timothy Rapp; Elcin Zan
Journal:  AACE Clin Case Rep       Date:  2021-06-18

8.  Fibroblast Growth Factor 23-Producing Phosphaturic Mesenchymal Tumor with Extraordinary Morphology Causing Oncogenic Osteomalacia.

Authors:  Cornelia Then; Evelyn Asbach; Harald Bartsch; Niklas Thon; Christian Betz; Martin Reincke; Ralf Schmidmaier
Journal:  Medicina (Kaunas)       Date:  2020-01-16       Impact factor: 2.430

Review 9.  Detection Rate of Culprit Tumors Causing Osteomalacia Using Somatostatin Receptor PET/CT: Systematic Review and Meta-Analysis.

Authors:  Marie Meyer; Marie Nicod Lalonde; Nathalie Testart; Mario Jreige; Christel Kamani; Sarah Boughdad; Barbara Muoio; Fabio Becce; Niklaus Schaefer; Christian Candrian; Luca Giovanella; John O Prior; Giorgio Treglia; Martin Riegger
Journal:  Diagnostics (Basel)       Date:  2019-12-18

10.  A Case of Tumor-Induced Osteomalacia: Finding the Culprit Acetabular Tumor and Successful Resection with a Novel Hip Joint-Preserving Surgery.

Authors:  Christie G Turin; Robert J Wilson; Ciera Mangone; Karen Rosenspire; Jessica Berman; Michelle Walker; Ravi Amaravadi; Mona Al Mukaddam
Journal:  J Orthop Case Rep       Date:  2021-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.